Goldman Sachs Maintains Neutral on HUTCHMED (China), Lowers Price Target to $14

Benzinga · 1d ago
Goldman Sachs analyst Paul Choi maintains HUTCHMED (China) (NASDAQ:HCM) with a Neutral and lowers the price target from $16 to $14.